---
title: "Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection: Safety questions"
description: "Safety questions on Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects and Monitoring. Questions: What are the most common side effects of Biktarvy? What side effects were reported after switching to Biktarvy? Does Biktarvy cause weight gain? Does Biktarvy raise serum creatinine? 6 further questions follow. 10 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/safety"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection: Safety questions

Manufacturer: Gilead Sciences, Inc.  
Prescribing information: [Biktarvy](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf)

## Side effects

<a id="biktarvy-side-effects"></a>

### What are the most common side effects of Biktarvy?

> “Most common adverse reactions (incidence ≥5%; all grades) in clinical studies through week 144 were diarrhea (6%), nausea (6%), and headache (5%).”

Source: [BIKTARVY: Important Safety Information, captured 2026-11-12](https://www.biktarvyhcp.com/important-safety-information#:~:text=Most%20common%20adverse%20reactions%20%28incidence,nausea%20%286%25%29%2C%20and%20headache%20%285%25%29.)

> “The most common adverse reactions (all Grades) reported in at least 5% of participants 
> in the BIKTARVY group in either Trial 1489 or Trial 1490 were diarrhea, nausea, and 
> headache. The proportion of participants who discontinued treatment through Week 144 
> with BIKTARVY, abacavir [ABC]/dolutegravir [DTG]/ lamivudine [3TC]), or DTG + 
> FTC/TAF, due to adverse events, regardless of severity, was 1%, 2%, and 2%, 
> respectively. Table 1 displays the frequency of adverse reactions (all Grades) greater 
> than or equal to 2% in the BIKTARVY group.”

Source: [BIKTARVY: Prescribing information, page 8, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=8)

> “Table 1 
> Adverse Reactions<sup>a</sup> (All Grades) Reported in ≥ 2% of Adults with HIV-
> 1 and No Antiretroviral Treatment History Receiving BIKTARVY in 
> Trials 1489 or 1490 (Week 144 analysis) 
> Trial 1489 
> Trial 1490 
> Adverse Reactions 
> BIKTARVY 
> N=314 
> ABC/DTG/3TC 
> N=315 
> BIKTARVY 
> N=320 
> DTG + FTC/TAF 
> N=325 
> Diarrhea 
> 6% 
> 4% 
> 3% 
> 3% 
> Nausea 
> 6% 
> 18% 
> 3% 
> 5% 
> Headache 
> 5% 
> 5% 
> 4% 
> 3% 
> Fatigue 
> 3% 
> 4% 
> 2% 
> 2% 
> Abnormal dreams 
> 3% 
> 3% 
> <1% 
> 1% 
> Dizziness 
> 2% 
> 3% 
> 2% 
> 1% 
> Insomnia 
> 2% 
> 3% 
> 2% 
> <1% 
> Abdominal distention 
> 2% 
> 2% 
> 1% 
> 2% 
> a. 
> Frequencies of adverse reactions are based on all adverse events attributed to trial drugs by the investigator. No 
> adverse reactions of Grade 2 or higher occurred in > 1% of participants treated with BIKTARVY.”

Source: [BIKTARVY: Prescribing information, page 8, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=8)

> “Additional adverse reactions (all Grades) occurring in less than 2% of participants 
> administered BIKTARVY in Trials 1489 and 1490 included vomiting, flatulence, 
> dyspepsia, abdominal pain, rash, and depression.”

Source: [BIKTARVY: Prescribing information, page 8, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=8)

> “Suicidal ideation, suicide attempt, and depression suicidal occurred in 2% of 
> participants administered BIKTARVY; these events occurred primarily in participants 
> with a preexisting history of depression, prior suicide attempt or psychiatric illness.”

Source: [BIKTARVY: Prescribing information, page 8, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=8)

> “The majority (84%) of adverse events associated with BIKTARVY were Grade 1.”

Source: [BIKTARVY: Prescribing information, page 8, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=8)

Note: Each row of Table 1 lists values in header order: BIKTARVY and ABC/DTG/3TC (Trial 1489), then BIKTARVY and DTG + FTC/TAF (Trial 1490).

<a id="biktarvy-switch-side-effects"></a>

### What side effects were reported after switching to Biktarvy?

> “Study 1844
>
> ARs (All Grades) Reported in ≥ 2% of Adults Who Received BIKTARVY<sup>†</sup>
>
> BIKTARVY
>
> (n=282)
>
> ABC/
> DTG/3TC
>
> (n=281)
>
> Headache, %
>
> 2
>
> 3
>
> Flatulence, %
>
> 0
>
> 2
>
> Nausea, %
>
> 0
>
> 2
>
> Diarrhea, %
>
> 1
>
> 1”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/safety-tolerability/treatment-naive#:~:text=Study%201844,1)

> “Study 1878
>
> BIKTARVY
>
> (n=290)
>
> ATV- or
> DRV-based
> Regimen
>
> (n=287)
>
> 5
>
> 0
>
> 2
>
> 0
>
> 2
>
> 0
>
> 2
>
> 0”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/safety-tolerability/treatment-naive#:~:text=Study%201878,0)

> “<sup>†</sup>Frequencies of ARs are based on all adverse events attributed to trial drugs by the investigator. No ARs of Grade 2 or higher occurred in >1% of participants treated with BIKTARVY.<sup>2</sup>
>
> The majority of ARs associated with BIKTARVY were Grade 1 in Study 1844 (58%) and in Study 1878 (76%)<sup>2</sup>
> The safety profile of BIKTARVY in the extension phases through Week 96 and Week 168 was similar to that in the randomized phases of Studies 1878 and 1844, respectively<sup>9,10</sup>
> Overall, the safety profile of BIKTARVY in virologically suppressed adults was similar to that in treatment-naïve adults<sup>4</sup>
> The most common ARs (incidence ≥5%; all grades) in clinical trials of treatment-naïve adults who received BIKTARVY were diarrhea, nausea, and headache<sup>4</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/safety-tolerability/treatment-naive#:~:text=The%20majority%20of%20ARs%20associated,BIKTARVY%20were%20diarrhea%2C%20nausea%2C%20and)

> “Study 4030
>
> ARs (All Grades) Reported in ≥2% of Virologically Suppressed Adults
>
> BIKTARVY
> (n=284)
>
> DTG+FTC/TAF
> (n=281)
>
> Abnormal dreams, %
>
> 2
>
> 1
>
> Weight increased, %
>
> 2
>
> 1
>
> Diarrhea, %
>
> 1
>
> 2
>
> Headache, %
>
> 1
>
> 2”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/safety-tolerability/treatment-naive#:~:text=ARs%20%28All%20Grades%29%20Reported%20in%20%E2%89%A52%25%20of%20Virologically,2)

> “Study 1961
>
> ARs (All Grades) Reported in >1 Virologically Suppressed Adult Woman Who Received BIKTARVY
>
> BIKTARVY
> (n=234)
>
> INSTI-or PI-
> based Regimen
> (n=236)
>
> Iron deficiency anemia, %
>
> 1
>
> 0
>
> Nausea, %
>
> 1
>
> 0
>
> Vomiting, %
>
> 1
>
> 0
>
> Through Week 48, no woman discontinued due to AEs in either treatment arm<sup>11</sup>
> The safety profile of BIKTARVY in the extension phase through Week 96 was similar to that in the randomized phase of Study 1961<sup>12</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/safety-tolerability/treatment-naive#:~:text=ARs%20%28All%20Grades%29%20Reported%20in%20%3E1,the%20randomized%20phase%20of%20Study)

> “ARs at Week 24 (All Grades)
> Reported in ≥1% of Adults Who
> Switched to BIKTARVY<sup>2</sup>
>
> BIKTARVY
> (n=330)
>
> SBR
> (No Switch at Baseline)
> (n=165)
>
> Diarrhea, %
>
> 2
>
> 0
>
> Flatulence, %
>
> 2
>
> 0
>
> Abnormal dreams, %
>
> 1
>
> 0
>
> Headache, %
>
> 1
>
> 0
>
> Nausea, %
>
> 1
>
> 0
>
> The most common ARs reported (all grades) in ≥1% of participants initially randomized to BIKTARVY through Week 48 (n=493) were weight increase (2%), flatulence (1%), abnormal dreams (1%), diarrhea (1%), headache (1%)<sup>2</sup>
> The most common ARs in the extension through Week 72 were similar to those observed in participants who received BIKTARVY through Week 48<sup>2</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/safety-tolerability/treatment-naive#:~:text=ARs%20at%20Week%2024%20%28All,who%20received%20BIKTARVY%20through%20Week)

Note: On the page, the Study 1878 columns share the Study 1844 row labels; its values are listed in the order Headache, Flatulence, Nausea, Diarrhea, BIKTARVY then comparator.

<a id="biktarvy-weight-gain"></a>

### Does Biktarvy cause weight gain?

> “Study 4030
>
> ARs (All Grades) Reported in ≥2% of Virologically Suppressed Adults
>
> BIKTARVY
> (n=284)
>
> DTG+FTC/TAF
> (n=281)
>
> Abnormal dreams, %
>
> 2
>
> 1
>
> Weight increased, %
>
> 2
>
> 1
>
> Diarrhea, %
>
> 1
>
> 2
>
> Headache, %
>
> 1
>
> 2”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/safety-tolerability/treatment-naive#:~:text=ARs%20%28All%20Grades%29%20Reported%20in%20%E2%89%A52%25%20of%20Virologically,2)

> “The most common ARs reported (all grades) in ≥1% of participants initially randomized to BIKTARVY through Week 48 (n=493) were weight increase (2%), flatulence (1%), abnormal dreams (1%), diarrhea (1%), headache (1%)<sup>2</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/safety-tolerability/treatment-naive#:~:text=The%20most%20common%20ARs%20reported,dreams%20%281%25%29%2C%20diarrhea%20%281%25%29%2C%20headache)

> “The following events have been identified during post approval use of BIKTARVY or 
> products containing TAF. Because these events are reported voluntarily from a 
> population of uncertain size, it is not always possible to reliably estimate their frequency 
> or establish a causal relationship to drug exposure.”

Source: [BIKTARVY: Prescribing information, page 11, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=11)

> “Investigations 
> Weight increased”

Source: [BIKTARVY: Prescribing information, page 11, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=11)

> “Median weight at baseline was 81 kg in the BIKTARVY arm and 82 kg in the FTC/TAF+DTG arm<sup>3</sup>”

Source: [BIKTARVY: Explore now, page 13, captured 2026-11-12](https://www.biktarvyhcp.com/-/media/documents/dyad-hcp-leave-behind.pdf#page=13)

> “Numerically greater weight gain was observed at Week 48 in participants switching from  
> TDF-based regimens (+2.2 kg) compared with those remaining on TAF-based regimens (+0.6 kg)<sup>3</sup>”

Source: [BIKTARVY: Explore now, page 13, captured 2026-11-12](https://www.biktarvyhcp.com/-/media/documents/dyad-hcp-leave-behind.pdf#page=13)

> “No difference in median change from baseline in 
> fasting lipids and weight was observed between 
> BIKTARVY and FTC/TAF+DTG at Week 48<sup>3</sup>”

Source: [BIKTARVY: Explore now, page 13, captured 2026-11-12](https://www.biktarvyhcp.com/-/media/documents/dyad-hcp-leave-behind.pdf#page=13)

> “Safety and tolerability analyses were summarized using descriptive statistics. The clinical 
> significance of these findings is unknown.<sup>3,4</sup>”

Source: [BIKTARVY: Explore now, page 13, captured 2026-11-12](https://www.biktarvyhcp.com/-/media/documents/dyad-hcp-leave-behind.pdf#page=13)

Note: The weight data in the linked PDF cite Sax et al., Clin Infect Dis 2021, which the virologically suppressed page lists as the Study 4030 publication.

<a id="biktarvy-long-term-side-effects"></a>

### What are the long-term side effects of Biktarvy?

> “Study 1489
>
> ARs (All Grades) Reported in ≥2% of Adults Who Received BIKTARVY
>
> BIKTARVY (Baseline-W240)
> (n=314)
>
> Switched
> from ABC/
> DTG/3TC to
> BIKTARVY (W144-240)
> (n=254)
>
> Headache, %
>
> 5
>
> <1
>
> Diarrhea, %
>
> 6
>
> 1
>
> Nausea, %
>
> 5
>
> <1
>
> Fatigue, %
>
> 3
>
> 0
>
> Abnormal dreams, %
>
> 3
>
> <1
>
> Dizziness, %
>
> 2
>
> 0
>
> Insomnia, %
>
> 2
>
> 0
>
> Proteinuria, %
>
> 0
>
> 0”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/safety-tolerability/treatment-naive#:~:text=ARs%20%28All%20Grades%29%20Reported%20in,0)

> “No treatment-naïve adults discontinued BIKTARVY due to renal-, hepatic-, or bone-related adverse events through Week 240<sup>1,3,5</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/safety-tolerability/treatment-naive#:~:text=No%20treatment%2Dna%C3%AFve%20adults%20discontinued%20BIKTARVY,bone%2Drelated%20adverse%20events%20through%20Week)

Note: Study 1489 data cover Weeks 0 to 240 for adults randomized to Biktarvy and Weeks 144 to 240 for adults who switched from ABC/DTG/3TC to Biktarvy at Week 144. The page lists the Study 1490 values without row labels, so they are not quoted here.

## Monitoring

<a id="biktarvy-serum-creatinine"></a>

### Does Biktarvy raise serum creatinine?

> “Changes in Serum Creatinine: BIC has been shown to increase serum creatinine due to 
> inhibition of tubular secretion of creatinine without affecting renal glomerular function 
> [see Clinical Pharmacology (12.2)]. Increases in serum creatinine occurred by Week 4 
> of treatment and remained stable through Week 144. In Trials 1489 and 1490, median 
> (Q1, Q3) serum creatinine increased by 0.11 (0.03, 0.19) mg per dL from baseline to 
> Week 144 in the BIKTARVY group and was similar to the comparator groups who 
> received ABC/DTG/3TC, or DTG + FTC/TAF.  There were no discontinuations due to 
> renal adverse events and renal serious adverse events were encountered in less than 
> 1% of participants treated with BIKTARVY through Week 144 in clinical trials.”

Source: [BIKTARVY: Prescribing information, page 10, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=10)

## Safety

<a id="biktarvy-kidney-problems"></a>

### Can Biktarvy cause kidney problems?

> “New onset or worsening renal impairment: Postmarketing cases of renal impairment, including acute renal failure, proximal renal tubulopathy (PRT), and Fanconi syndrome have been reported with tenofovir alafenamide (TAF)–containing products. Do not initiate BIKTARVY in patients with estimated creatinine clearance (CrCl) <30 mL/min except in virologically suppressed adults <15 mL/min who are receiving chronic hemodialysis. Patients with impaired renal function and/or taking nephrotoxic agents (including NSAIDs) are at increased risk of renal-related adverse reactions. Discontinue BIKTARVY in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome.”

Source: [BIKTARVY: Important Safety Information, captured 2026-11-12](https://www.biktarvyhcp.com/important-safety-information#:~:text=New%20onset%20or%20worsening%20renal,or%20evidence%20of%20Fanconi%20syndrome.)

> “Renal monitoring: Prior to or when initiating BIKTARVY and during therapy, assess serum creatinine, CrCl, urine glucose, and urine protein in all patients as clinically appropriate. In patients with chronic kidney disease, assess serum phosphorus.”

Source: [BIKTARVY: Important Safety Information, captured 2026-11-12](https://www.biktarvyhcp.com/important-safety-information#:~:text=Renal%20monitoring%3A%20Prior%20to%20or,kidney%20disease%2C%20assess%20serum%20phosphorus.)

<a id="biktarvy-overdose"></a>

### What happens after a Biktarvy overdose?

> “No data are available on overdose of BIKTARVY in patients. If overdose occurs, 
> monitor the patient for evidence of toxicity. Treatment of overdose with BIKTARVY 
> consists of general supportive measures including monitoring of vital signs as well as 
> observation of the clinical status of the patient. 
> Hemodialysis treatment removes approximately 30% of the FTC dose over a 3-hour 
> dialysis period starting within 1.5 hours of FTC dosing (blood flow rate of 400 mL/min 
> and a dialysate flow rate of 600 mL/min). It is not known whether FTC can be removed 
> by peritoneal dialysis. 
> Tenofovir is efficiently removed by hemodialysis with an extraction coefficient of 
> approximately 54%.”

Source: [BIKTARVY: Prescribing information, page 19, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=19)

<a id="biktarvy-boxed-warning"></a>

### What is the Biktarvy boxed warning about hepatitis B after stopping treatment?

> “BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B
> Severe acute exacerbations of hepatitis B have been reported in patients with HIV-1 and HBV who have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of BIKTARVY. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients with HIV-1 and HBV who discontinue BIKTARVY. If appropriate, anti-hepatitis B therapy may be warranted.”

Source: [BIKTARVY: Important Safety Information, captured 2026-11-12](https://www.biktarvyhcp.com/important-safety-information#:~:text=BOXED%20WARNING%3A%20POST%20TREATMENT%20ACUTE,B%20therapy%20may%20be%20warranted.)

> “Prior to or when initiating: Test patients for HBV infection.”

Source: [BIKTARVY: Important Safety Information, captured 2026-11-12](https://www.biktarvyhcp.com/important-safety-information#:~:text=Prior%20to%20or%20when%20initiating%3A%20Test%20patients%20for%20HBV%20infection.)

<a id="biktarvy-warnings"></a>

### What are the warnings and precautions for Biktarvy?

> “Drug interactions: See Contraindications and Drug Interactions sections. Consider the potential for drug interactions prior to and during BIKTARVY therapy and monitor for adverse reactions.
> Immune reconstitution syndrome, including the occurrence of autoimmune disorders with variable time to onset, has been reported.
> New onset or worsening renal impairment: Postmarketing cases of renal impairment, including acute renal failure, proximal renal tubulopathy (PRT), and Fanconi syndrome have been reported with tenofovir alafenamide (TAF)–containing products. Do not initiate BIKTARVY in patients with estimated creatinine clearance (CrCl) <30 mL/min except in virologically suppressed adults <15 mL/min who are receiving chronic hemodialysis. Patients with impaired renal function and/or taking nephrotoxic agents (including NSAIDs) are at increased risk of renal-related adverse reactions. Discontinue BIKTARVY in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome.
> Renal monitoring: Prior to or when initiating BIKTARVY and during therapy, assess serum creatinine, CrCl, urine glucose, and urine protein in all patients as clinically appropriate. In patients with chronic kidney disease, assess serum phosphorus.
> Lactic acidosis and severe hepatomegaly with steatosis: Fatal cases have been reported with the use of nucleoside analogs, including FTC and TDF. Discontinue BIKTARVY if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity develop, including hepatomegaly and steatosis in the absence of marked transaminase elevations.”

Source: [BIKTARVY: Important Safety Information, captured 2026-11-12](https://www.biktarvyhcp.com/important-safety-information#:~:text=Drug%20interactions%3A%20See%20Contraindications%20and,absence%20of%20marked%20transaminase%20elevations.)

<a id="biktarvy-contraindications"></a>

### What are the contraindications for Biktarvy?

> “BIKTARVY® is contraindicated with two medications: dofetilide and rifampin”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/safety-tolerability/contraindications-ddis#:~:text=BIKTARVY%C2%AE%20is%20contraindicated%20with%20two%20medications%3A%20dofetilide%20and%20rifampin)

> “BIKTARVY is contraindicated to be co-administered with: 
>
> • dofetilide due to the potential for increased dofetilide plasma concentrations and 
> associated serious and/or life-threatening events [see Drug Interactions (7.5)]. 
>
> • rifampin due to decreased BIC plasma concentrations, which may result in the 
> loss of therapeutic effect and development of resistance to BIKTARVY [see Drug 
> Interactions (7.5)].”

Source: [BIKTARVY: Prescribing information, page 5, captured 2026-11-12](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf#page=5)

## Related pages
- [Medical information: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide): HIV-1 infection](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection)
- [Indication](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/guidelines)
